Bryce A. Harrison, Framingham, MA (US); James E. Dowling, Lexington, MA (US); Matthew G. Bursavich, Needham, MA (US); Dawn M. Troast, Bedford, MA (US); Blaise S. Lippa, Newton, MA (US); Bruce N. Rogers, Belmont, MA (US); Kristopher N. Hahn, Medford, MA (US); Cheng Zhong, Belmont, MA (US); Qi Qiao, Natick, MA (US); Fu-Yang Lin, Sudbury, MA (US); Brian Sosa, Cambridge, MA (US); Aleksey I. Gerasyuto, Flemington, NJ (US); Andrea Bortolato, Metuchen, NJ (US); Mats A. Svensson, New York, NY (US); Eugene Hickey, Danbury, CT (US); Kyle D. Konze, Brooklyn, NY (US); Tyler Day, New York, NY (US); and Byungchan Kim, West New York, NJ (US)
Assigned to Morphic Therapeutic, Inc., Waltham, MA (US)
Filed by Morphic Therapeutic, Inc., Waltham, MA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/239,045.
Application 17/239,045 is a continuation of application No. 17/001,086, filed on Aug. 24, 2020, granted, now 11,021,480.
Application 17/001,086 is a continuation of application No. 16/555,589, filed on Aug. 29, 2019, abandoned.
Claims priority of provisional application 62/859,457, filed on Jun. 10, 2019.
Claims priority of provisional application 62/724,423, filed on Aug. 29, 2018.
Prior Publication US 2022/0073511 A1, Mar. 10, 2022
